OPKO Health, Inc.
- Home
- Companies
- OPKO Health, Inc.
- Products
- OPKO Somatrogon - Long-Acting Human ...
OPKO Somatrogon - Long-Acting Human Growth Hormone (hGH) Molecule
Somatrogon, a long-acting human growth hormone (hGH) molecule, is a once-weekly injectable, created using recombinant technology, for the treatment of pediatric and adult growth hormone deficiency (GHD). The molecule consists of the natural peptide sequence of native growth hormone and the 28 amino acids of the C-Terminus Peptide (CTP) of the human chorionic gonadotropin hormone. This molecule, as compared to current GH replacement therapies, is intended to reduce the injection frequency from a daily to once a week in adults and children with GHD.
Most popular related searches
growth hormone
human chorionic gonadotropin
hormone deficiency
hormone human
pediatry
injectable technology
Therapeutic Area
Endocrinology
Indication
hGH Deficiency and other related conditions
Clinical Trial Status
Adult: Phase 3 Completed
Pediatrics: Phase 3 Complete, OLE in Progress
Partnerships
Pfizer, Inc.